Dasatinib and Quercetin (DQ) demonstrate superior efficacy over Navitoclax in mitigating intervertebral disc degeneration in a senescence-driven mouse model. This study utilizes SM/J mice to explore the role of premature disc cell senescence in early-onset degeneration, highlighting that while Navitoclax did not yield improvements in degeneration or senescence status, DQ treatment resulted in significantly lower degeneration grades and reduced senescence markers, such as p19ARF and p21.

The findings underscore the therapeutic potential of DQ, which not only improved disc cell viability and phenotype retention but also slowed fibrosis in the nucleus pulposus tissue. Transcriptomic analysis indicated that DQ treatment affected cell cycle regulation and JNK signaling across various tissues, suggesting a broader impact on cellular health. Notably, shared signaling targets, including Junb and Zfp36l1, were identified in both SM/J and C57BL/6 N mice, reinforcing the treatment’s relevance across genetic backgrounds.

This research shifts the paradigm for senolytic therapies, emphasizing the need for comparative studies among first-generation treatments. The demonstrated effectiveness of DQ in reducing senescence and SASP in human degenerated nucleus pulposus cells suggests a viable pathway for clinical applications in treating disc degeneration. As the field of aging biology progresses, these findings advocate for increased focus on affordable senolytic strategies, potentially expediting drug development timelines and expanding therapeutic options for age-related degenerative conditions.

Source: fightaging.org